Neonatal Klebsiella pneumonia sepsis and imipenem/cilastatin

Related Experiment Video

Updated: Oct 16, 2026

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

R Oral1, M Akisü, N Kültürsay

  • 1Ege University Medical Faculty, Department of Pediatrics, Izmir, Turkey.

Indian Journal of Pediatrics
|April 20, 2000
PubMed

Insights

Imipenem/cilastatin shows high efficacy in treating neonatal Klebsiella pneumonia sepsis, significantly improving cure and discharge rates. However, increased risk of Candida albicans superinfection requires careful monitoring.

Area of Science:

  • Neonatal Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Neonatal sepsis caused by Klebsiella pneumoniae presents a significant challenge.
  • Conventional antibiotic regimens have limitations in treating severe neonatal infections.

Purpose of the Study:

  • To investigate the efficacy and safety of imipenem/cilastatin for neonatal Klebsiella pneumonia sepsis.
  • To compare outcomes with conventional antibiotic treatment.

Main Methods:

  • A comparative study involving 45 infants treated with imipenem/cilastatin and 39 control infants on conventional antibiotics.
  • Antimicrobial susceptibility testing was performed.

Main Results:

  • Imipenem demonstrated high susceptibility (94%) in the study group.
  • Imipenem/cilastatin significantly reduced mortality (11% vs 69%), increased cure rates (73% vs 28%), and improved sequelae-free discharge (67% vs 23%).
  • Adverse effects included Candida albicans superinfection (20%) and transient liver/renal function impairment (19%/10%).

Conclusions:

  • Imipenem/cilastatin is an effective alternative for neonatal Klebsiella pneumonia sepsis.
  • Awareness of potential Candida albicans superinfection is crucial when using imipenem/cilastatin.

More Related Videos

Establishment of A Mouse Sepsis-Induced Immunosuppression Model By Intranasal Instillation of Bacteria05:40

Establishment of A Mouse Sepsis-Induced Immunosuppression Model By Intranasal Instillation of Bacteria

Published on: June 12, 2026

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...